Daniel F Mackay1, Emma R Russell1, Katy Stewart1, John A MacLean1, Jill P Pell1, William Stewart1. 1. From the Institute of Health and Wellbeing (D.F.M., J.P.P.), the Institute of Neuroscience and Psychology (E.R.R., W.S.), and the Institute of Cardiovascular and Medical Sciences (K.S., J.A.M.), University of Glasgow, the Hampden Sports Clinic, Hampden Stadium (K.S., J.A.M.), and the Department of Neuropathology, Queen Elizabeth University Hospital (W.S.) - all in Glasgow, United Kingdom.
Abstract
BACKGROUND: Neurodegenerative disorders have been reported in elite athletes who participated in contact sports. The incidence of neurodegenerative disease among former professional soccer players has not been well characterized. METHODS: We conducted a retrospective cohort study to compare mortality from neurodegenerative disease among 7676 former professional soccer players (identified from databases of Scottish players) with that among 23,028 controls from the general population who were matched to the players on the basis of sex, age, and degree of social deprivation. Causes of death were determined from death certificates. Data on medications dispensed for the treatment of dementia in the two cohorts were also compared. Prescription information was obtained from the national Prescribing Information System. RESULTS: Over a median of 18 years, 1180 former soccer players (15.4%) and 3807 controls (16.5%) died. All-cause mortality was lower among former players than among controls up to the age of 70 years and was higher thereafter. Mortality from ischemic heart disease was lower among former players than among controls (hazard ratio, 0.80; 95% confidence interval [CI], 0.66 to 0.97; P = 0.02), as was mortality from lung cancer (hazard ratio, 0.53; 95% CI, 0.40 to 0.70; P<0.001). Mortality with neurodegenerative disease listed as the primary cause was 1.7% among former soccer players and 0.5% among controls (subhazard ratio [the hazard ratio adjusted for competing risks of death from ischemic heart disease and death from any cancer], 3.45; 95% CI, 2.11 to 5.62; P<0.001). Among former players, mortality with neurodegenerative disease listed as the primary or a contributory cause on the death certificate varied according to disease subtype and was highest among those with Alzheimer's disease (hazard ratio [former players vs. controls], 5.07; 95% CI, 2.92 to 8.82; P<0.001) and lowest among those with Parkinson's disease (hazard ratio, 2.15; 95% CI, 1.17 to 3.96; P = 0.01). Dementia-related medications were prescribed more frequently to former players than to controls (odds ratio, 4.90; 95% CI, 3.81 to 6.31; P<0.001). Mortality with neurodegenerative disease listed as the primary or a contributory cause did not differ significantly between goalkeepers and outfield players (hazard ratio, 0.73; 95% CI, 0.43 to 1.24; P = 0.24), but dementia-related medications were prescribed less frequently to goalkeepers (odds ratio, 0.41; 95% CI, 0.19 to 0.89; P = 0.02). CONCLUSIONS: In this retrospective epidemiologic analysis, mortality from neurodegenerative disease was higher and mortality from other common diseases lower among former Scottish professional soccer players than among matched controls. Dementia-related medications were prescribed more frequently to former players than to controls. These observations need to be confirmed in prospective matched-cohort studies. (Funded by the Football Association and Professional Footballers' Association.).
BACKGROUND: Neurodegenerative disorders have been reported in elite athletes who participated in contact sports. The incidence of neurodegenerative disease among former professional soccer players has not been well characterized. METHODS: We conducted a retrospective cohort study to compare mortality from neurodegenerative disease among 7676 former professional soccer players (identified from databases of Scottish players) with that among 23,028 controls from the general population who were matched to the players on the basis of sex, age, and degree of social deprivation. Causes of death were determined from death certificates. Data on medications dispensed for the treatment of dementia in the two cohorts were also compared. Prescription information was obtained from the national Prescribing Information System. RESULTS: Over a median of 18 years, 1180 former soccer players (15.4%) and 3807 controls (16.5%) died. All-cause mortality was lower among former players than among controls up to the age of 70 years and was higher thereafter. Mortality from ischemic heart disease was lower among former players than among controls (hazard ratio, 0.80; 95% confidence interval [CI], 0.66 to 0.97; P = 0.02), as was mortality from lung cancer (hazard ratio, 0.53; 95% CI, 0.40 to 0.70; P<0.001). Mortality with neurodegenerative disease listed as the primary cause was 1.7% among former soccer players and 0.5% among controls (subhazard ratio [the hazard ratio adjusted for competing risks of death from ischemic heart disease and death from any cancer], 3.45; 95% CI, 2.11 to 5.62; P<0.001). Among former players, mortality with neurodegenerative disease listed as the primary or a contributory cause on the death certificate varied according to disease subtype and was highest among those with Alzheimer's disease (hazard ratio [former players vs. controls], 5.07; 95% CI, 2.92 to 8.82; P<0.001) and lowest among those with Parkinson's disease (hazard ratio, 2.15; 95% CI, 1.17 to 3.96; P = 0.01). Dementia-related medications were prescribed more frequently to former players than to controls (odds ratio, 4.90; 95% CI, 3.81 to 6.31; P<0.001). Mortality with neurodegenerative disease listed as the primary or a contributory cause did not differ significantly between goalkeepers and outfield players (hazard ratio, 0.73; 95% CI, 0.43 to 1.24; P = 0.24), but dementia-related medications were prescribed less frequently to goalkeepers (odds ratio, 0.41; 95% CI, 0.19 to 0.89; P = 0.02). CONCLUSIONS: In this retrospective epidemiologic analysis, mortality from neurodegenerative disease was higher and mortality from other common diseases lower among former Scottish professional soccer players than among matched controls. Dementia-related medications were prescribed more frequently to former players than to controls. These observations need to be confirmed in prospective matched-cohort studies. (Funded by the Football Association and Professional Footballers' Association.).
Authors: Kevin F Bieniek; Owen A Ross; Kerry A Cormier; Ronald L Walton; Alexandra Soto-Ortolaza; Amelia E Johnston; Pamela DeSaro; Kevin B Boylan; Neill R Graff-Radford; Zbigniew K Wszolek; Rosa Rademakers; Bradley F Boeve; Ann C McKee; Dennis W Dickson Journal: Acta Neuropathol Date: 2015-10-30 Impact factor: 17.088
Authors: T M McMillan; P McSkimming; J Wainman-Lefley; L M Maclean; J Hay; A McConnachie; W Stewart Journal: J Neurol Neurosurg Psychiatry Date: 2016-10-07 Impact factor: 10.154
Authors: Lea T Grinberg; Renato Anghinah; Camila Fernandes Nascimento; Edson Amaro; Renata P Leite; Maria da Graça M Martin; Michel S Naslavsky; Leonel T Takada; Wilson Jacob Filho; Carlos A Pasqualucci; Ricardo Nitrini Journal: J Alzheimers Dis Date: 2016-07-29 Impact factor: 4.472
Authors: William Stewart; Kieren Allinson; Safa Al-Sarraj; Corbin Bachmeier; Karen Barlow; Antonio Belli; Mark P Burns; Alan Carson; Fiona Crawford; Kristen Dams-O'Connor; Ramon Diaz-Arrastia; C Edward Dixon; Brian L Edlow; Scott Ferguson; Bruce Fischl; Rebecca D Folkerth; Steve Gentleman; Christopher C Giza; M Sean Grady; Adel Helmy; Mark Herceg; Janice L Holton; David Howell; Peter J Hutchinson; Diego Iacono; Juan E Iglesias; Milos D Ikonomovic; Victoria E Johnson; C Dirk Keene; Julia K Kofler; Vassilis E Koliatsos; Edward B Lee; Harvey Levin; Jonathan Lifshitz; Helen Ling; David J Loane; Seth Love; Andrew Ir Maas; Niklas Marklund; Christina L Master; Damien M McElvenny; David F Meaney; David K Menon; Thomas J Montine; Benoit Mouzon; Elliott J Mufson; Joseph O Ojo; Mayumi Prins; Tamas Revesz; Craig W Ritchie; Colin Smith; Richard Sylvester; Cheuk Y Tang; John Q Trojanowski; Kathryn Urankar; Robert Vink; Cheryl Wellington; Elisabeth A Wilde; Lindsay Wilson; Keith Yeates; Douglas H Smith Journal: Lancet Neurol Date: 2019-02-12 Impact factor: 44.182
Authors: Carlos A Celis-Morales; Donald M Lyall; Paul Welsh; Jana Anderson; Lewis Steell; Yibing Guo; Reno Maldonado; Daniel F Mackay; Jill P Pell; Naveed Sattar; Jason M R Gill Journal: BMJ Date: 2017-04-19
Authors: Emma R Russell; Katy Stewart; Daniel F Mackay; John MacLean; Jill P Pell; William Stewart Journal: BMJ Open Date: 2019-05-22 Impact factor: 2.692
Authors: Carrie Esopenko; Jessica Meyer; Elisabeth A Wilde; Amy D Marshall; David F Tate; Alexander P Lin; Inga K Koerte; Kimberly B Werner; Emily L Dennis; Ashley L Ware; Nicola L de Souza; Deleene S Menefee; Kristen Dams-O'Connor; Dan J Stein; Erin D Bigler; Martha E Shenton; Kathy S Chiou; Judy L Postmus; Kathleen Monahan; Brenda Eagan-Johnson; Paul van Donkelaar; Tricia L Merkley; Carmen Velez; Cooper B Hodges; Hannah M Lindsey; Paula Johnson; Andrei Irimia; Matthew Spruiell; Esther R Bennett; Ashley Bridwell; Glynnis Zieman; Frank G Hillary Journal: Brain Imaging Behav Date: 2021-01-06 Impact factor: 3.978
Authors: Volker Krutsch; Werner Krutsch; Jonas Härtl; Hendrik Bloch; Volker Alt; Christian Klein; Claus Reinsberger; Robin Seiffert; Lorenz Huber; Johannes Weber Journal: PLoS One Date: 2021-08-11 Impact factor: 3.240
Authors: Emma R Russell; Thomas McCabe; Daniel F Mackay; Katy Stewart; John A MacLean; Jill P Pell; William Stewart Journal: J Neurol Neurosurg Psychiatry Date: 2020-07-21 Impact factor: 10.154
Authors: Gill Livingston; Jonathan Huntley; Andrew Sommerlad; David Ames; Clive Ballard; Sube Banerjee; Carol Brayne; Alistair Burns; Jiska Cohen-Mansfield; Claudia Cooper; Sergi G Costafreda; Amit Dias; Nick Fox; Laura N Gitlin; Robert Howard; Helen C Kales; Mika Kivimäki; Eric B Larson; Adesola Ogunniyi; Vasiliki Orgeta; Karen Ritchie; Kenneth Rockwood; Elizabeth L Sampson; Quincy Samus; Lon S Schneider; Geir Selbæk; Linda Teri; Naaheed Mukadam Journal: Lancet Date: 2020-07-30 Impact factor: 79.321